Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.
Cooperation possibilities
At TANDEM, we believe in the transformative potential of targeting the extracellular matrix (ECM) to address a wide range of medical challenges. We invite partners to collaborate with us in leveraging our expertise in ECM targeting to develop innovative solutions across various therapeutic areas.
- https://tandem-tx.com/
- +41 44 633 69 21
- Send an email
- Dr. Mamta Chabria
